Ionis Looks Ahead To Commercializing Its Own Products

 
• By Joseph Haas

Beyond its cardiovascular partnership with AstraZeneca, Ionis is getting ready to launch antisense drugs for familial chylomicronemia syndrome and hereditary angioedema.

Ionis is anticipating two near-term launches of wholly owned products. (Shutterstock)

More from Earnings

More from R&D